LEO Pharma unveiled new data analyzing the long-term therapeutic response of treatment with Adbry (tralokinumab-ldrm) in adults with moderate-to-severe atopic dermatitis (AD). The findings were shared via an e-poster at the 82nd American Academy of Dermatology (AAD) Congress in San Diego.[1]

“The data presented for Adbry at AAD further builds upon an established, wide-ranging collection of clinical evidence that aims to improve the support for those living with moderate-to-severe AD,” Brian Hilberdink, EVP and President, Region North America, LEO Pharma, said in a company news release. “Following the expansion of our indication in the US late last year for Adbry to encompass pediatric patients aged 12 to 17 years old, this data is the latest, positive step on our ongoing mission to maximize the treatment options available for as many people as possible who live with this condition.”

The post hoc analysis included 347 adults (18 years and above) with moderate-to-severe AD who were continuously treated with Adbry for 52 weeks in the phase 3 ECZTRA 1 and 2 trials and subsequently for up to 152 weeks in the ECZTEND open-label extension trial.[1]

Assessments in this analysis focused on timepoints after week 16 in ECZTEND to allow for re-normalization of response rates due to variable time between the last treatment in the parent trial and the first treatment in ECZTEND. The analysis showed that more than 70% of patients who continued treatment with Adbry in ECZTEND maintained a stable Eczema Area and Severity Index (EASI) score (≤7, no to mild disease) at ≥80% of days and over half of responders maintained stable EASI ≤7 at 100% of days for up to three years.[1]

Adbry (tralokinumab-ldrm), which is marketed outside of the U.S. under the tradename Adtralza (tralokinumab), is a high-affinity fully human monoclonal antibody developed to bind to and inhibit the interleukin (IL)-13 cytokine. Adbry is approved for the treatment of adults and pediatric patients (12 years and above) with moderate-to-severe AD in the US, Canada, the European Union, the United Arab Emirates, Great Britain, and South Korea. Adtralza is approved for use in adults with moderate-to-severe AD in Saudi Arabia, Switzerland, and Japan.

References

1. Blauvelt A, et al. Stability of long-term therapeutic responses to tralokinumab in adults with moderate-to-severe atopic dermatitis. Presented at the 2024 American Academy of Dermatology Annual Meeting; March 8-12 2024; San Diego, CA.